Market Overview

Perrigo Launches betamethason valerate foam 0.12% Commercially

Related PRGO
The Year-End Tax-Selling Strategy
Perrigo's Weak Near-Term Outlook Is Concerning
Mallinckrodt Post-FTC Settlement: Buy The Dip Or Valeant-Lite? (Seeking Alpha)

Perrigo Company (Nasdaq: PRGO) today announced that it has begun commercial shipments of betamethasone valerate foam 0.12%, the generic equivalent of Luxiq® Foam, consistent with the date certain launch settlement previously announced. Cobrek Pharmaceuticals, Inc. ("Cobrek"), which was recently acquired by Perrigo, was first to file, making the product eligible for 180 days of marketing exclusivity. Perrigo is entitled to receive 100% of the profits from net sales of the product due to the Cobrek acquisition.

Betamethasone valerate foam 0.12% is indicated for the relief of corticosteroid-responsive skin conditions of the scalp (scalp psoriasis). Brand annual sales were approximately $40 million as measured by Symphony Health.

Posted-In: News FDA


Related Articles (PRGO)

View Comments and Join the Discussion!